PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'China National Biotec Group Company Limited, Beijing, 100024, China.\', \'Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.\', \'Beijing Institute of Biological Products, China National Biotec Group Company Limited, Beijing, 100176, China.\', \'National Vaccine and Serum Institute, China National Biotec Group Company Limited, Beijing, 101111, China.\', \'Department of Infectious Diseases, Research Laboratory of Clinical Virology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. zhangx@shsmu.edu.cn.\', \'China National Biotec Group Company Limited, Beijing, 100024, China. yangxiaoming@sinopharm.com.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1007/s11684-021-0914-x
?:hasPublicationType
?:journal
  • Frontiers of medicine
is ?:pmid of
?:pmid
?:pmid
  • 35122211
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 0.913
?:rankingScore_hIndex
  • 25
is ?:relation_isRelatedTo_publication of
?:title
  • Early assessment of the safety and immunogenicity of a third dose (booster) of COVID-19 immunization in Chinese adults.
?:type
?:year
  • 2022

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/35122211>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/35122211>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all